Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of AXS-07 in Migraine
NCT04068051Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dapagliflozin + saxagliptin in migraine, sponsored by Axsome Therapeutics, Inc. Primary endpoint: Long-term Safety of Chronic Intermittent Use of AXS-07 at 12 months. Started Jul 2019; status: completed.
02
Drugs
dapagliflozin + saxagliptin
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04068051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068051.